cnslogo%20largest_edited.png

Investment Fund Exit Strategy

Although the Center naturally favors opportunities where liquidation can be affected as expeditiously as possible, we realize that the CNS drug discovery and development process is a lengthy one, and may require seed funding that spans the course of a number of years. Although initial public offerings are always a possible exit event, the most likely exit event for the Center is a buy-out by a venture capital firm or a pharmaceutical company looking for a promising investment.

© 2020 by Center for Neurologic Study.